The USPTO grants CovalX a new patent for the analysis of Therapeutic Protein Aggregates in the USA
Zürich - February 16th 2011
The United States Patent and Trademark Office (USPTO) has granted a US Patent (12/448.313) to CovalX AG (Schlieren), claiming for a new method to characterize therapeutic protein aggregates based on MALDI mass spectrometry.
The method of the invention allows the direct analysis of therapeutic protein aggregqates in a very broad mass range (currently up to 2 MDa) with nM sensitivity. The method can be applied in most formulation buffers and allows to characterize the stoechiometry and the ratios of the aggregates detected.
The method takes benefits of specially developed cross-linking molecules, allowing fast and efficient stabilization of the aggregates and a unique high-mass detection system allowing nM detection of the complexes up to 2 MDa.
The patented method is currently used in CovalX CRO laboratory and help pharmaceutical and biotechnology companies to better understand their therapeutic proteins.